I believe what it will do, and maybe the mouse mod

I believe what it will do, and maybe the mouse models will help here, is turn a fast-moving cancer into slow-moving cancer. So not exactly a cure, but suppresses the disease, like with HIV it reduces the VL, and with cancer it reduces the metastasis in mice by 98%, but if they stop giving the mice leronlimab, the cancer might return and start spreading. RP has said maybe make cancer a chronic condition.

Cancer is easier to treat if it is stays isolated to the initial site. So the chemo/radiation with leronlimab should work in combo to push it into remission.

With CTCs, it will give the patients a good idea of their current status, because larger ctc numbers is strongly connected to metastasis.

I like using these CTC numbers more, even after remission. I had an aunt that died from breast cancer. She first went into remission and then finally moved her to 6 month checkups. On one of those checkups, they found the cancer had came back and spread to the point it was too late, though she put up a resilient fight. With these CTC numbers, maybe they can check more frequently for people in remission. I'm not sure on their ultimate plan of when to stop giving the patient leronlimab. Though if it were me, I would want to continue taking it in remission.


https://www.nature.com/articles/srep43464
Abstract

Quote:

---

Whether circulating tumor cells (CTCs) can be used as an indicator of treatment response in breast cancer (BC) needs to be clarified. We addressed this issue by a meta-analysis. PubMed, EMBase and Cochrane library databases were searched in June 2016. Effect measures were estimated as pooled risk ratio (RR), odds ratio (OR) or mean difference by fixed- or random-effect models, according to heterogeneity of included studies. In total, 50 studies with 6712 patients were recruited. Overall analysis showed that there was a significant reduction of CTC-positive rate (RR = 0.68, 95% CI: 0.61–0.76, P < 0.00001) after treatment. Subgroup analyses revealed that neoadjuvant treatment, adjuvant treatment, metastatic treatment or combination therapy could reduce the CTC-positive rate, but surgery could not; moreover, the reduction was only found in HER2+ or HER2- patients but not in the triple-negative ones. Reduction of CTC-positive rate was associated with lower probability of disease progression (OR = 0.54, 95% CI: 0.33–0.89, P = 0.01) and longer overall survival period (mean difference = 11.61 months, 95% CI: 8.63–14.59, P < 0.00001) as well as longer progression-free survival period (mean difference = 5.07 months, 95% CI: 2.70–7.44, P < 0.0001). These results demonstrate that CTC status can serve as an indicator to monitor the effectiveness of treatments and guide subsequent therapies in BC.

---

Read More: https://investorshangout.com/post/view?id=533...z5h7PgI85H